Table 2.
Baseline characteristics of HCV infection, liver disease, and laboratory parameters in LTFU and patients with SVR assessment
| Parameter | LTFU, n=509 | Patients with SVR assessment, n=18,354 | p |
|---|---|---|---|
| Genotype, n (%) | <0.0001 | ||
| 1 | 6 (1.2) | 370 (2.0) | |
| 1a | 28 (5.5) | 830 (4.5) | |
| 1b | 289 (56.8) | 13,616 (74.2) | |
| 2 | 4 (0.8) | 49 (0.3) | |
| 3 | 133 (26.1) | 2203 (12.0) | |
| 4 | 34 (6.7) | 880 (4.8) | |
| 5 | 0 | 1 (<0.1) | |
| 6 | 0 | 6 (<0.1) | |
| No data | 15 (2.9) | 399 (2.2) | |
| GT3 / non-GT3, n (%) | 133 (26.1) / 361 (70.9) | 2203 (12.0) / 16,149 (88) | <0.0001 |
| Liver fibrosis n (%) | |||
| F0 | 11 (2.2) | 512 (2.8) | 0.44 |
| F1 | 181 (35.6) | 7195 (39.2) | |
| F2 | 107 (21) | 3430 (18.7) | |
| F3 | 70 (13.7) | 2477 (13.5) | |
| F4 | 120 (23.6) | 4433 (24.2) | |
| No data | 20 (3.9) | 307 (1.7) | |
| F0-3 / F4, n (%) | 369 (72.5) / 120 (23.6) | 13614 (74.2) / 4433 (24.2) | 0.99 |
| History of liver decompensation, n (%) | |||
| Ascites | 17 (3.3) | 483 (2.6) | 0.172 |
| Encephalopathy | 1 (0.2) | 130 (0.7) | 0.542 |
| Documented esophageal varices, n (%) | 34 (6.7) | 1259 (6.9) | 0.92 |
| Liver decompensation at baseline, n (%) | |||
| Ascites | 12 (2.4) | 263 (1.4) | 0.17 |
| Encephalopathy | 2 (0.4) | 102 (0.6) | >0.99 |
| HCC history, n (%) | 12 (2.4) | 260 (1.4) | 0.077 |
| OLTx history, n (%) | 1 (0.2) | 143 (0.8) | 0.19 |
| ALT IU/L, median (IQR) | 62 (39–101.8) | 60 (37.5–100) | 0.48 |
| Bilirubin mg/dL, median (IQR) | 0.7 (0.5–1) | 0.64 (0.5–0.9) | 0.64 |
| Albumin g/dL, median (IQR) | 4.1 (3.8–4.5) | 4.13 (3.8–4.4) | 0.54 |
| Creatinine mg/dL, median (IQR) | 0.8 (0.7–0.9) | 0.8 (0.7–0.9) | 0.09 |
| Hemoglobin g/dL, median (IQR) | 14.3 (13.1–15.5) | 14.5 (13.4–15.5) | 0.0526 |
| Platelets, ×1000/µL, median (IQR) | 194 (138–240) | 197 (146–245) | 0.27 |
| INR, median (IQR) | 1 (1–1.1) | 1 (1–1.1) | 0.27 |
| HCV RNA ×105 IU/ml, median (IQR) | 7.97 (2.56–24) | 9.93 (3.21–26.1) | 0.009 |
Abbreviations: ALT alanine transaminase, GT genotype, HCC hepatocellular carcinoma, HCV hepatitis C virus, INR international normalized ratio, IQR interquartile range, F fibrosis stage, OLTx orthotopic liver transplantation, LTFU loss to follow-up, SVR sustained virological response